Delivery Order SPE2DB24D8003-SPE2DB25FJUBK

Award Date 3/25/25
Potential Completion Date 3/26/25
Potential Value $1.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of DEXMETHYLPHENIDATE ER 5 MG CAP 100S. The contract has a firm fixed price of $1,343.71 and an ultimate completion date of October 29, 2024. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This IDC, part of the DLA Troop Support...
This federal contract award, with an ID of SPE2DX15D8003|SPE2DX24F7E4Q, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $1,738.14 firm fixed-price delivery order is for the supply of 4565030170 - DEXTROAMP-AMPHETAMIN 10 MG TAB 100S, a pharmaceutical product, with a period of performance through July 1, 2024. The contract does not have a set-aside...
This federal contract award, with ID SPE2DB24D8002|SPE2DB25FJNGX, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of DEXMETHYLPHENIDATE ER 10 MG CP 100S, a pharmaceutical product, with a ceiling value of $1,372.59. It is a firm fixed price delivery order contract with a completion date of March 12, 2025. Dakota Drug, Inc. is an established federal contractor, holding a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,611.66, is for the delivery of dextroamphetamine-amphetamine 10 mg tablets. The contract has a firm fixed price and is set to expire on June 20, 2024. Dakota Drug, Inc. also holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,025.79, is for the provision of 10 mg tablet formulations of the medication dextroamphetamine-amphetamine. This order is part of a larger single-award Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc., valued at $999,999,999.00, which allows the company to supply a...
The Defense Logistics Agency (DLA) awarded a $5,476.61 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4,565,321,317 units of Methylphenidate ER 18 mg tablets. This order falls under Dakota Drug, Inc.'s existing Indefinite Delivery Contract (IDC) SPE2DB24D8001, valued at $999,999,999.00, which allows the company to provide a wide range of pharmaceutical products, medical supplies, and healthcare equipment to...
This federal contract award, with an ID of SPE2DX15D8003|SPE2DX24F7D3K, is a delivery order awarded to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract, worth $1,434.57, is for the supply of 4564298515 - Dexmethylphenidate ER 20 MG Capsules in quantities of 100. The award was made by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense, and does not have a set-aside...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of lisdexamfetamine 50 mg capsules, a pharmaceutical product. The contract has a ceiling value of $2,326.86 and a completion date of December 18, 2024. This contract is not set aside for any special designation. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, identified as...
This federal contract award, identified as SPE2DX15D8002|SPE2DX23F2WY7, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $2,781.02 firm fixed-price delivery order is for the provision of FOCALIN XR 20 MG CAPSULE 100S, a pharmaceutical product, to support the DLA's Troop Support Medical operations. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, identified as...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKZDT, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of pharmaceutical products, medical supplies, and healthcare equipment, primarily to support U.S. Armed Forces medical operations. The contract has a ceiling value of $1,528.94 and is a Firm Fixed Price Delivery Order. It is not associated with a set-aside program. Dakota...
  • SPE2DB24D8003
    Indefinite Delivery Contract
  • SPE2DB24D8003-SPE2DB25FJUBK
    Delivery Order

This federal contract award, identified as SPE2DB24D8003|SPE2DB25FJUBK, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,091.68 firm fixed-price delivery order is for the provision of 4567690394 DEXTROAMPHETAMINE ER 15 MG CAP 90S, a pharmaceutical product. The contract has a performance period extending through March 26, 2025.

Dakota Drug, Inc. is also the holder of a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This IDC, which is part of the DLA Troop Support Medical's ECAT Generation V Program, allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. The IDC has a performance period extending through December 31, 2025.

Generated 6/24/25, 9:48 AM